Delphia (USA)’s Viking Therapeutics VKTX Stock Holding History

Delphia (USA)’s Portfolio VKTX Stock Details VKTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-13,468	Closed	-$62K	–	409
2021 Q4	$62K	Buy	+13,468	New	+$75.5K	0.07%	262

Other funds holding VKTX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

PWAM

Park West Asset Management San Francisco, California $1.47B AUM 86.42% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

SCM

Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return

Delphia (USA)'s VKTX Position: Q1 2022 in Review

Delphia (USA) sold out of Viking Therapeutics (VKTX) in Q1 2022, closing a stake of 13,468 shares — an estimated $62K sold.

Delphia (USA) first reported a position in VKTX in Q4 2021 and held it in 1 quarter. The position peaked at $62K in Q4 2021. 140 funds tracked by Wall St. Rank hold VKTX as of Q1 2022.

Delphia (USA) reported no remaining Viking Therapeutics position as of Q1 2022 after selling out during the quarter.
Delphia (USA) sold 13,468 Viking Therapeutics shares in Q1 2022, an estimated $62K.
Delphia (USA) first reported a position in Viking Therapeutics in Q4 2021 and held it in 1 quarter.
Delphia (USA)'s Viking Therapeutics position peaked at $62K in Q4 2021.
140 funds tracked by Wall St. Rank held Viking Therapeutics as of Q1 2022.

Based on Delphia (USA)'s 13F filing for Q1 2022, filed 16 May 2022.